A convergence of patent cliffs and pharmacoeconomic pressures is forcing a historic restructuring of the entire drug development model. At first glance, the resurgence of M&A in the sector appears to be a simple story of abundant capital. Pharmaceutical giants are rich with cash, biotechnology valuations remain attractive relative to their pandemic-era peaks, and executives are once again rolling out balance sheets after several years of caution. This is anything but. What ap

Balancing Regulatory Standards with the Need for Rare Disease Innovation

Why Eli Lilly paid a massive premium for Centessa's narcolepsy platform and what it signals for the future of neuro-biotech M&A.

With a novel RNA-based drug for IBD, the French biotech has become the most strategic M&A target of the year. We dissect the competing rationales.

A nearly billion-dollar wave of investment from two pharma titans reveals a fierce new competition to control the future of drug discovery in South Korea.

Why the Supreme Court’s latest decision changes the biopharma playbook, affects global supply chains, and questions Trump's executive leverage.